Baird analyst Michael Ha raised the firm’s price target on Astrana Health to $67 from $54 and keeps an Outperform rating on the shares. The firm called the company a Top Pick and believes the company is grossly undervalued and on the precipice of unlocking a wealth of growth.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
Questions or Comments about the article? Write to editor@tipranks.com